REG - CVS Group plc - Transaction in Own Shares
Today 07:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251211:nRSK1001La&default-theme=true
RNS Number : 1001L CVS Group plc 11 December 2025
11 December 2025
CVS GROUP plc
("CVS" or the "Company" and, together with its subsidiaries, the "Group")
Transaction in own shares
CVS announces that on 10 December 2025 it purchased the following number of
its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg,
Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the
terms of the share buyback programme announced on 24 October 2025 (the "Share
Buyback Programme").
Date of purchase: 10/12/2025
Aggregate number of Ordinary Shares purchased: 24,425
Lowest price paid per share (GBp): 1,218.00
Highest price paid per share (GBp): 1,236.00
Volume weighted average price paid per share (GBp): 1,228.06
CVS intends to cancel all of the purchased Ordinary Shares.
Following settlement of the above purchases and cancellation of the Ordinary
Shares purchased, CVS will have 70,891,292 Ordinary Shares in issue and
holds no Ordinary Shares in treasury.
The total number of voting rights in CVS is therefore 70,891,292 and this
figure may be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change to their interest in, CVS under the Financial Conduct Authority's
Disclosure and Transparency Rules.
Since the commencement of the Share Buyback Programme, the Company has
repurchased 849,491 Ordinary Shares in aggregate at a weighted average price
of 1,215.79 pence per share.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market
Abuse Regulation), as it forms part of Retained EU Law as defined in the
European Union (Withdrawal) Act 2018, the table below contains detailed
information of the individual trades made by Berenberg as part of the Share
Buyback Programme.
Individual transactions:
Number of Transaction price (GBp share) Time of Transaction Trading Venue
Ordinary Shares purchased transaction (UK Time) reference number
632 1236 10/12/2025 09:03:02 1348989714704231 XLON
451 1236 10/12/2025 09:03:04 1348989714704235 XLON
139 1232 10/12/2025 09:32:26 1348989714706519 XLON
716 1232 10/12/2025 09:32:29 1348989714706527 XLON
702 1232 10/12/2025 10:04:10 1348989714708739 XLON
735 1230 10/12/2025 10:05:00 1348989714708840 XLON
737 1234 10/12/2025 10:41:39 1348989714711036 XLON
749 1234 10/12/2025 10:41:39 1348989714711040 XLON
71 1234 10/12/2025 10:41:44 1348989714711042 XLON
772 1232 10/12/2025 10:42:01 1348989714711060 XLON
34 1232 10/12/2025 10:44:01 1348989714711276 XLON
183 1232 10/12/2025 10:45:00 1348989714711369 XLON
60 1232 10/12/2025 10:45:00 1348989714711370 XLON
809 1234 10/12/2025 11:03:49 1348989714712577 XLON
848 1234 10/12/2025 11:23:22 1348989714713696 XLON
200 1234 10/12/2025 11:24:53 1348989714713773 XLON
869 1232 10/12/2025 11:27:19 1348989714713967 XLON
128 1232 10/12/2025 11:38:26 1348989714714838 XLON
292 1232 10/12/2025 11:38:26 1348989714714839 XLON
98 1232 10/12/2025 11:38:26 1348989714714840 XLON
108 1232 10/12/2025 11:41:33 1348989714715129 XLON
344 1232 10/12/2025 11:41:33 1348989714715130 XLON
229 1232 10/12/2025 11:43:56 1348989714715381 XLON
897 1232 10/12/2025 11:45:06 1348989714715526 XLON
900 1232 10/12/2025 11:55:24 1348989714716317 XLON
583 1232 10/12/2025 11:55:24 1348989714716322 XLON
462 1232 10/12/2025 11:55:57 1348989714716361 XLON
246 1232 10/12/2025 11:55:57 1348989714716362 XLON
415 1232 10/12/2025 11:56:02 1348989714716395 XLON
189 1232 10/12/2025 12:02:20 1348989714717078 XLON
150 1230 10/12/2025 12:02:20 1348989714717083 XLON
228 1230 10/12/2025 12:02:20 1348989714717084 XLON
171 1226 10/12/2025 12:03:01 1348989714717176 XLON
607 1226 10/12/2025 12:03:01 1348989714717177 XLON
775 1224 10/12/2025 12:12:16 1348989714717969 XLON
522 1224 10/12/2025 12:16:59 1348989714718444 XLON
751 1224 10/12/2025 12:18:43 1348989714718586 XLON
554 1224 10/12/2025 12:18:43 1348989714718591 XLON
423 1218 10/12/2025 12:20:08 1348989714718770 XLON
318 1218 10/12/2025 12:20:08 1348989714718771 XLON
182 1220 10/12/2025 12:27:25 1348989714719216 XLON
552 1220 10/12/2025 12:27:25 1348989714719217 XLON
6 1220 10/12/2025 12:38:53 1348989714719982 XLON
7 1220 10/12/2025 12:38:53 1348989714719983 XLON
3 1220 10/12/2025 12:38:53 1348989714719984 XLON
542 1220 10/12/2025 12:42:01 1348989714720209 XLON
182 1220 10/12/2025 12:42:01 1348989714720210 XLON
44 1222 10/12/2025 13:04:03 1348989714721785 XLON
10 1222 10/12/2025 13:04:03 1348989714721786 XLON
96 1222 10/12/2025 13:04:03 1348989714721787 XLON
48 1222 10/12/2025 13:04:03 1348989714721788 XLON
684 1224 10/12/2025 13:45:41 1348989714725418 XLON
509 1224 10/12/2025 13:45:41 1348989714725422 XLON
11 1224 10/12/2025 13:45:41 1348989714725423 XLON
200 1222 10/12/2025 14:06:54 1348989714727650 XLON
699 1220 10/12/2025 14:22:33 1348989714728978 XLON
140 1218 10/12/2025 14:22:35 1348989714728984 XLON
714 1218 10/12/2025 14:34:55 1348989714731296 XLON
204 1218 10/12/2025 14:36:01 1348989714731495 XLON
67 1218 10/12/2025 14:36:01 1348989714731496 XLON
258 1218 10/12/2025 14:39:12 1348989714732195 XLON
451 1224 10/12/2025 15:09:05 1348989714738505 XLON
291 1224 10/12/2025 15:09:05 1348989714738506 XLON
237 1222 10/12/2025 15:17:32 1348989714740270 XLON
96 1222 10/12/2025 15:21:54 1348989714741540 XLON
72 1222 10/12/2025 15:26:49 1348989714742410 XLON
23 1220 10/12/2025 15:35:04 1348989714743809 XLON
Contacts
CVS Group
plc
via Camarco
Richard Fairman, CEO
Robin Alfonso, CFO
Paul Higgs, Chief Veterinary Officer
Charlotte Page, Head of Investor Relations
Peel Hunt LLP (Nominated Adviser & Joint
Broker)
+44 (0)20 7418 8900
Christopher Golden / James Steel / Andrew Clark
Berenberg (Joint
Broker)
+44 (0)20 3207 7800
Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing
Camarco (Financial PR)
cvsg@camarco.co.uk
Ginny
Pulbrook
+44 (0)7961 315 138
Letaba Rimell
Tilly Butcher
About CVS Group plc (www.cvsukltd.co.uk)
CVS Group is an AIM-listed provider of veterinary services with operations in
the UK and Australia. CVS is focused on providing high-quality clinical
services to its clients and their animals, with outstanding and dedicated
clinical teams and support colleagues at the core of its strategy.
The Group now operates c.470 veterinary practices across its two territories,
including specialist referral hospitals and dedicated out-of-hours sites.
Alongside the core Veterinary Practices division, CVS operates Laboratories
(providing diagnostic services to CVS and third-parties) and an online retail
business ("Animed Direct").
The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and
c.3,300 nurses.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END POSGPGBCPUPAPGU
Copyright 2019 Regulatory News Service, all rights reservedRecent news on CVS
See all newsREG - CVS Group plc - Standard form for notification of major holdings
AnnouncementREG - CVS Group plc - Update on move to the Main Market
AnnouncementREG - CVS Group plc - Transaction in Own Shares
AnnouncementREG - CVS Group plc - Transaction in Own Shares
AnnouncementREG - CVS Group plc - Transaction in Own Shares
Announcement